Overview

Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
0
Participant gender:
All
Summary
The main purpose of this study is to evaluate the safety and efficacy of Rituximab combined with chemotherapy in CD20+ adult acute lymphoblastic leukemia.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ruijin Hospital
Treatments:
6-Mercaptopurine
Asparaginase
Cyclophosphamide
Cytarabine
Dexamethasone
Doxorubicin
Mercaptopurine
Methotrexate
Prednisone
Rituximab
Vincristine
Criteria
Inclusion Criteria:

- Diagnosis of CD20-positive ALL

- Adequate liver function (bilirubin less than or equal to 1.5*ULN, unless considered
due to tumor), and renal function (creatinine less than or equal to 1.5*ULN, unless
considered due to tumor)

- Signed informed consent

Exclusion Criteria:

- Prior history of treatment with high-dose Ara-C, MTX or rituximab

- Pregnant or lactating women

- History of allergy to rituximab

- Unable to sign informed consent

- Active replication of HBV

- History of stem cell transplantation